Advertisement

Corrigendum to “518 Poster - BluePrint molecular subtyping recognizes single and dual subtype tumors with consequences for therapeutic guidance” [Eur J Cancer 138 (Supplement 1) (October 2020) S106–S107]

      The order of Authors given in the original publication has been incorrectly listed. The correct order of Authors is:
      Midas M. Kuilman, Architha Ellappalayam, Lorenza Mittempergher, Diederik Wehkamp, Bob Chan, Rajith Bhaskaran, Annuska M. Glas
      These corrections have also been applied to the original article.

      Linked Article

      • BluePrint molecular subtyping recognizes single and dual subtype tumors with consequences for therapeutic guidance
        European Journal of CancerVol. 138
        • Preview
          Background: BluePrint (BP) is an 80-gene molecular subtyping test that classifies early breast cancer into functional Luminal, HER2, and Basal types1. BP Luminal type is further stratified into A- and B-type using MammaPrint, the 70-gene test for Low and High Risk of distant relapse2. The BP subtype of a patient is determined by a score for each subtype based on the expression of the BP signature genes. In regular diagnostics, tumor samples with a “single BP subtype” have the highest score for that specific subtype, and lower scores for the other subtypes.
        • Full-Text
        • PDF